Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.

Cancer chemotherapy and pharmacology - 1 Oct 2016

Gota Vikram, Chinnaswamy Girish, Vora Tushar, Rath Sanhita, Yadav Akanksha, Gurjar Murari, Veal Gareth, Kurkure Purna

Abstract excerpt

PURPOSE: To compare the pharmacokinetics of 13-cis retinoic acid (13-cisRA) between Indian and UK neuroblastoma patients receiving comparable treatment, alongside measures of toxicity and response. METHODS: 13-cisRA (160 mg/m(2)/day) was administered to 36 patients ≤16 years in two divided doses. Plasma 13-cisRA concentrations were determined on days 1 and 14 of cycles 1 and 4 of treatment. Area under the plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP2C8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Glucuronosyltransferase

Share to Neuroblastoma

Share to Pharmacogenetics

Share to Survival Analysis

Share to United Kingdom

Source

Identifiers

PMID: 27541143
DOI: 10.1007/s00280-016-3126-3

Genes

EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.PMID 27541143Read ↗

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.Semantic proximity Read ↗

Metabolic characteristics of 13‐cis‐retinoic acid (isotretinoin) and anti‐tumour activity of the 13‐cis‐retinoic acid metabolite 4‐oxo‐13‐cis‐retinoic acid in neuroblastomaSemantic proximity Read ↗

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Semantic proximity Read ↗

Prevalence of advanced bone age in a cohort of patients who received cis‐retinoic acid for high‐risk neuroblastomaSemantic proximity Read ↗

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialSemantic proximity Read ↗

Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid.Semantic proximity Read ↗

Retinoids and the control of growth/death decisions in human neuroblastoma cell linesSemantic proximity Read ↗

Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic DifferentiationSemantic proximity Read ↗

Enhancing Retinoic Acid-mediated Effects Through Inhibition of CYP26A1, CYP26B1 and HGF Signaling in Neuroblastoma CellsSemantic proximity Read ↗

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cellsSemantic proximity Read ↗

Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.Semantic proximity Read ↗

p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS–KCNR human neuroblastoma cell lineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.